The Role of Gut Microbiota and Diet on Uremic Retention Solutes Production in the Context of Chronic Kidney Disease

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2018 Apr 14

PMID 29652797

Citations 42

Authors

Laetitia Koppe

Denis Fouque

Christophe O Soulage

Affiliations

Soon will be listed here.

Abstract

Uremic retention solutes (URS) are associated with cardiovascular complications and poor survival in chronic kidney disease. The better understanding of the origin of a certain number of these toxins enabled the development of new strategies to reduce their production. URS can be classified according to their origins (i.e., host, microbial, or exogenous). The discovery of the fundamental role that the intestinal microbiota plays in the production of many URS has reinstated nutrition at the heart of therapeutics to prevent the accumulation of URS and their deleterious effects. The intestinal microbiota is personalized and is strongly influenced by dietary habits, such as the quantity and the quality of dietary protein and fibers. Herein, this review out lines the role of intestinal microbiota on URS production and the recent discoveries on the effect of diet composition on the microbial balance in the host with a focus on the effect on URS production.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.

Amino acid metabolism in kidney health and disease.

Knol M, Wulfmeyer V, Muller R, Rinschen M Nat Rev Nephrol. 2024; 20(12):771-788.

PMID: 39198707 DOI: 10.1038/s41581-024-00872-8.

Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease.

Liabeuf S, Hafez G, Pesic V, Spasovski G, Bobot M, Maciulaitis R Clin Kidney J. 2024; 17(8):sfae174.

PMID: 39114495 PMC: 11304602. DOI: 10.1093/ckj/sfae174.

Displacing the Burden: A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease.

Sanchez-Ospina D, Mas-Fontao S, Gracia-Iguacel C, Avello A, Gonzalez de Rivera M, Mujika-Marticorena M J Clin Med. 2024; 13(5).

PMID: 38592263 PMC: 10934686. DOI: 10.3390/jcm13051428.

Conservative Management in End-Stage Kidney Disease between the Dialysis Myth and Neglected Evidence-Based Medicine.

Martino F, Novara G, Nalesso F, Calo L J Clin Med. 2024; 13(1).

PMID: 38202048 PMC: 10779521. DOI: 10.3390/jcm13010041.

References

Koppe L, Fouque D . Microbiota and prebiotics modulation of uremic toxin generation. Panminerva Med. 2016; 59(2):173-187. DOI: 10.23736/S0031-0808.16.03282-1. View

Krishnamurthy V, Wei G, Baird B, Murtaugh M, Chonchol M, Raphael K . High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 2011; 81(3):300-6. PMC: 4704855. DOI: 10.1038/ki.2011.355. View

Younes H, Egret N, Hadj-Abdelkader M, Remesy C, Demigne C, Gueret C . Fermentable carbohydrate supplementation alters nitrogen excretion in chronic renal failure. J Ren Nutr. 2006; 16(1):67-74. DOI: 10.1053/j.jrn.2005.10.007. View

Takayama F, Taki K, Niwa T . Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003; 41(3 Suppl 1):S142-5. DOI: 10.1053/ajkd.2003.50104. View

Kalantar-Zadeh K, Fouque D . Nutritional Management of Chronic Kidney Disease. N Engl J Med. 2017; 377(18):1765-1776. DOI: 10.1056/NEJMra1700312. View

Miller C, Corbin K, da Costa K, Zhang S, Zhao X, Galanko J . Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study. Am J Clin Nutr. 2014; 100(3):778-86. PMC: 4135488. DOI: 10.3945/ajcn.114.087692. View

Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y . Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996; 74(2):349-55. DOI: 10.1159/000189334. View

Koppe L, Mafra D, Fouque D . Probiotics and chronic kidney disease. Kidney Int. 2015; 88(5):958-66. DOI: 10.1038/ki.2015.255. View

Nicholson J, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W . Host-gut microbiota metabolic interactions. Science. 2012; 336(6086):1262-7. DOI: 10.1126/science.1223813. View

10.

Rothhammer V, Mascanfroni I, Bunse L, Takenaka M, Kenison J, Mayo L . Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016; 22(6):586-97. PMC: 4899206. DOI: 10.1038/nm.4106. View

11.

KLAHR S, Levey A, Beck G, Caggiula A, Hunsicker L, Kusek J . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994; 330(13):877-84. DOI: 10.1056/NEJM199403313301301. View

12.

Bliss D, Stein T, Schleifer C, Settle R . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. Am J Clin Nutr. 1996; 63(3):392-8. DOI: 10.1093/ajcn/63.3.392. View

13.

Elamin S, Alkhawaja M, Bukhamsin A, Idris M, Abdelrahman M, Abutaleb N . Gum Arabic Reduces C-Reactive Protein in Chronic Kidney Disease Patients without Affecting Urea or Indoxyl Sulfate Levels. Int J Nephrol. 2017; 2017:9501470. PMC: 5446885. DOI: 10.1155/2017/9501470. View

14.

Rampton D, Cohen S, Crammond V, Gibbons J, Lilburn M, Rabet J . Treatment of chronic renal failure with dietary fiber. Clin Nephrol. 1984; 21(3):159-63. View

15.

Vanholder R, Schepers E, Pletinck A, Nagler E, Glorieux G . The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014; 25(9):1897-907. PMC: 4147984. DOI: 10.1681/ASN.2013101062. View

16.

Zoccali C, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A . Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2002; 358(9299):2113-7. DOI: 10.1016/s0140-6736(01)07217-8. View

17.

Minakuchi H, Wakino S, Hosoya K, Sueyasu K, Hasegawa K, Shinozuka K . The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats. Nephrol Dial Transplant. 2015; 31(3):413-23. DOI: 10.1093/ndt/gfv367. View

18.

Ticak T, Kountz D, Girosky K, Krzycki J, Ferguson Jr D . A nonpyrrolysine member of the widely distributed trimethylamine methyltransferase family is a glycine betaine methyltransferase. Proc Natl Acad Sci U S A. 2014; 111(43):E4668-76. PMC: 4217433. DOI: 10.1073/pnas.1409642111. View

19.

Poesen R, Evenepoel P, de Loor H, Delcour J, Courtin C, Kuypers D . The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS One. 2016; 11(4):e0153893. PMC: 4839737. DOI: 10.1371/journal.pone.0153893. View

20.

Fouque D, Laville M . Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2009; (3):CD001892. DOI: 10.1002/14651858.CD001892.pub3. View